Chimeric antigen receptor (CAR) T-cells targeting CD19, CD20, and CD22 may be an effective salvage therapy for patients with B-lineage acute lymphoblastic leukemia (ALL), regardless of CD19 expression, according to research published in Leukemia.

While CAR T-cell therapy targeting CD19, a pan-B cell marker, has shown good efficacy in B-lineage ALL, up to 39% of patients will relapse after receiving this treatment. This, the authors note, is linked to the downregulation, but preservation, of CD20 and CD22 expression.

While CD19 is almost always expressed in B-lineage ALL, CD20 and CD22 are expressed in

about 50% and 80% to 90% of patients, respectively. Based on this observation, researchers hypothesized that targeting CD19, CD20, and CD22 together would improve the rate of durable responses in this patient group.


Continue Reading

For this study, researchers engineered T cells to cotarget CD19, CD20, and CD22, and evaluated their efficacy in vitro and in an animal model of CD19-negative disease. The CD19/CD20/CD22 CAR T-cells were used to target CD19-negative blasts from patients who has relapsed following CD19 CAR T-cell therapy and in CRISPR-edited CD19 knockout B-lineage ALL.

The cotargeting novel T cells killed the CD19-negative blasts and CRISPR/Cas9 CD19 knockouts more effectively than CD19 CAR T-cells. The engineered cells also formed immune synapses, mediating effective cytolytic complex formation.

Related Articles

T cells targeting CD19/CD20/CD22 were also effective in single-cell tracking studies, and appeared as effective as CD19-targeting T cells in CD19-positive disease.

“Although the toxicity of our CAR T-cell product will need to be assessed in carefully designed human trials, the effectiveness of CD19/[CD]20/[CD]22 CAR T-cells against CD19-[negative] escape [B-lineage]-ALL and CD19-[positive] [B-lineage]-ALL alike compares very favorably to that of the benchmark CD19 CAR T-cells,” the authors concluded.

Reference

Fousek K, Watanabe J, Joseph SK, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression [published online March 24, 2020]. Leukemia. doi: 10.1038/s41375-020-0792-2